AstraZeneca and Bristol-Myers Squibb Spark Mega Merger Rumors
A possible megamerger between AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) has sent shockwaves through the biopharma industry. The Financial Times reported on August 2 that the two companies are discussing a merger, which would be the largest in history.
Astra's shares fell by 8% on August 3 after the news broke, while Bristol's shares dropped about 1%. With market caps of around $260 billion for Astra and $130 billion for Bristol, it is likely that Astra would be the acquirer in this deal. The combined company would only trail Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV) in size.
According to Morningstar Equity Research, possible motivators for the merger could include complementary patent cliffs, access to specific pipeline programs, and geographic diversification. However, the integration of businesses would be a significant challenge, and there are also concerns about potential Federal Trade Commission issues due to the mutual oncology focus.
Morningstar analysts suggest that Astra's confidence in its ability to reach $80 billion in revenue by 2030 may be faltering (they model $71 billion), while Bristol may be concerned about risks surrounding its key pipeline assets, including milvexian and next-generation oral multiple myeloma therapies.